KAILA SAXE: Open Payments
NPI 1336491737 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$515 in 22 payments from 11 companies in 2025. Trend: 2023 $368 · 2024 $963 · 2025 $515
Food & beverage: $515
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 1 | $122 |
| PFIZER INC. | 4 | $100 |
| Dexcom, Inc. | 3 | $57 |
| Novo Nordisk Inc | 3 | $52 |
| Amgen Inc. | 3 | $46 |
| Lilly USA, LLC | 2 | $32 |
| Exact Sciences Corporation | 2 | $30 |
| Merck Sharp & Dohme LLC | 1 | $22 |
| IBSA Pharma Inc. | 1 | $20 |
| ABBVIE INC. | 1 | $20 |
Products named: AREXVY, NURTEC ODT, Dexcom G6 Transmitter, MOUNJARO, Ozempic, PREVNAR 20, OTEZLA, GARDASIL 9.
Industry payments across TX — which companies pay providers there.
